Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.0K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.0K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

64
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
64

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Prior Authorization Suspension on Access to Diabetes Technology in an Underserved Population: A Retrospective Analysis.

Diabetes care·2026
Same author

Insulin Costs and Use by Medicare Beneficiaries After the Inflation Reduction Act Out-of-Pocket Cap.

JAMA·2026
Same author

Cortisol's role in difficult-to-control type 2 diabetes: Insights from the CATALYST study-a plain language review.

Current medical research and opinion·2026
Same author

Challenges in and opportunities for individualising diabetes technology: a position statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group.

Diabetologia·2026
Same author

Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group.

Diabetes care·2026
Same author

Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report.

Journal of diabetes science and technology·2026

Related Experiment Video

Updated: Apr 4, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K

BIOSIMILARS AND NEW INSULIN VERSIONS.

Anne L Peters, R Daniel Pollom, Jason S Zielonka

    Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
    |September 5, 2015
    PubMed
    Summary

    New insulin versions and biosimilars are entering the market. Understanding manufacturing, regulatory pathways, and clinical use implications is crucial for healthcare providers when selecting biologic products.

    More Related Videos

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.9K
    A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
    09:35

    A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

    Published on: July 16, 2016

    11.8K

    Related Experiment Videos

    Last Updated: Apr 4, 2026

    An In Ovo Model for Testing Insulin-mimetic Compounds
    06:09

    An In Ovo Model for Testing Insulin-mimetic Compounds

    Published on: April 23, 2018

    11.2K
    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.9K
    A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
    09:35

    A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

    Published on: July 16, 2016

    11.8K

    Area of Science:

    • Pharmacology and Therapeutics
    • Biotechnology
    • Regulatory Science

    Background:

    • Patent expirations for biologics, including insulins, are enabling new market entrants.
    • The landscape of biologic therapeutics is expanding with biosimilars and novel insulin formulations.

    Purpose of the Study:

    • To offer clinicians a comprehensive overview of available similar biologic products in the U.S.
    • To elucidate key issues surrounding manufacturing, regulatory pathways, and clinical implications of these products.

    Main Methods:

    • A thorough review of pertinent clinical and regulatory literature was conducted.

    Main Results:

    • Similar biologic products, including new insulin versions, face complex development and approval processes, often utilizing distinct regulatory pathways (e.g., 351(k) biosimilar pathway, 505(b)(2) pathway).
    • Manufacturing variations can impact immunogenicity, safety, and efficacy.
    • Healthcare providers must grasp concepts like interchangeability, therapeutic equivalence, and switching for new insulin products.

    Conclusions:

    • Understanding the nuances of similar biologic products is essential for informed decision-making by physicians, payers, and patients.
    • Navigating the evolving market of biologics requires awareness of regulatory differences and clinical considerations.